News

Cellectis Unveils Advances in Gene Therapy at ESGCT Conference

Cellectis Unveils Advances in Gene Therapy at ESGCT Conference

Innovative Gene Therapy Insights from Cellectis

NEW YORK — Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS) is at the forefront of biotechnology, focusing on groundbreaking gene editing techniques to foster advancements in life-saving therapies. Their cutting-edge research was recently spotlighted at a prominent conference that gathered leading experts from the field.

Non-Viral Gene Editing Breakthrough

Cellectis introduced compelling data emphasizing the application of circular single-stranded DNA (CssDNA) as a transformative non-viral gene therapy template. This presentation showcased findings about the efficacy of CssDNA in enhancing genetic modifications within hematopoietic stem and progenitor cells (HSPCs), along with a comprehensive analysis of the safety of TALE base editors.

Poster Presentation Highlights

The poster titled Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs Editing was presented by Julien Valton, Ph.D., the Vice President of Gene Therapy at Cellectis. The findings revealed two critical outcomes:

  • CssDNA editing demonstrated a significant increase in gene insertion frequency within viable HSPCs.
  • CssDNA-optimized HSPCs exhibited a superior capability for engrafting and maintaining genetic changes in murine models compared to traditional adeno-associated virus (AAV) methods.

These outcomes strongly indicate CssDNA's potential as a streamlined and efficient mechanism for advancing gene therapy applications.

TALE Base Editing Safety Analysis

Another vital component of the research presented at the event was an exploration into TALE base editors (TALEB). This innovative editing tool merges a transcription activator-like effector domain with specialized enzymatic components that facilitate precise genetic edits without causing DNA breaks.

Comprehensive Safety Evaluation

Maria Feola, Ph.D., Senior Scientist and Team Leader at Cellectis, presented work on the safety profile of TALEB, which provided insights into potential off-target effects during the editing process. The analysis utilized advanced bioinformatics coupled with experimental validations, confirming no significant biases toward unintended C-to-T edits in the vicinity of essential genomic sites associated with DNA organization and expression.

These findings establish a robust foundation for the safe utilization of TALEB in future therapeutic applications aimed at both nuclear and mitochondrial genomes.

Future Perspectives on Gene Therapy

Cellectis continues to position itself as a leader in the biotechnology landscape by innovating within the realm of gene therapies. The company not only focuses on therapeutic applications but also incorporates a comprehensive approach from research and development through to manufacturing. Their allogeneic CAR T-cell therapies stand as a testament to their vision of delivering ready-to-use treatments designed to combat cancer effectively.

This integrated operation underlines Cellectis' unique capability to manage the entire gene therapy process, ensuring quality and efficiency at every stage. With its headquarters situated in Paris and additional locations in New York and Raleigh, North Carolina, Cellectis is well-positioned to meet the growing demands in the therapeutic landscape.

Contact Information for Further Inquiries

For more details on their presentations or inquiries about their ongoing research, interested parties can reach out to:

Media Contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Investor Relations:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Frequently Asked Questions

What recent advancements were shared by Cellectis at the ESGCT Congress?

Cellectis presented innovative data focusing on non-viral gene therapy using CssDNA and the safety analysis of TALE base editors.

Who were the key presenters at the event?

Julien Valton, Ph.D., presented on CssDNA, while Maria Feola, Ph.D., discussed TALE base editors' safety.

How does CssDNA improve gene therapy outcomes?

CssDNA enhances gene insertion frequency and improves engraftment success in stem cells compared to traditional methods.

What impact does the TALE base editing tool have?

TALEB allows precise edits in the DNA sequence without inducing breaks, which reduces potential for off-target effects.

How does Cellectis manage its gene therapy process?

Cellectis oversees the entire therapy production cycle, from development to manufacturing, ensuring quality and efficiency in treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 72

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 35

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 120

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Early Home Care Signals Families Should Not Ignore

Updated Category News Views 46

A pill organizer sitting untouched can say more than a family conversation ever will. Jay Mann of Amada Senior Care in Richmond points to a hard truth in HelloNation's Nov. 20, 2026 article: the need for in-home support often arrives quietly, disguised as little breaks in routines that everybody would rather wave away. This is not a matter for armchair diagnosis, and...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 31

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
.com/blog/news?page=2">More News Articles